A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors

Inclusion Criteria: * Male patients aged 15 years or older * Evidence of advanced NSGCT documented either by pathology or by elevated tumor markers (AFP or hCG) and a compatible clinical presentation * Primary site located in either the testis, the retroperitoneum or the mediastinum * Progressive disease after at least 2 lines of chemotherapy for advanced NSGCT (ie, non-stage I) * In case of brain metastases, confirm that patients should be stable / controlled with corticosteroid/anti seizures agents * No other progressive carcinoma within previous the 5 years, except for basal-cell carcinoma of the skin * Life expectancy \>/= 3 months * Adequate hematologic function : * Hemoglobin \>/= 10.0 g/dL * Absolute neutrophil count \>/= 1.5 x 10 \^ 9/L, * Platelet count \>/= 100 x 10 \^ 9/L, * Adequate organ function * Serum creatinine \< 1.5 x ULN. If serum creatinine 1.0 - 1.5 x ULN, creatinine clearance calculated (or measured) according to CKD-EPI formula (see Appendix B) \> 60 mL/min * AST/SGOT and ALT/SGPT \</= 1.5 x ULN * Bilirubin \</= 1.5 x ULN * Information delivered to patient and informed consent form signed by the patient or his legal representative * Patient affiliated to a social security system or beneficiary of the same Exclusion Criteria: * Patients receiving anti cancer therapy within 4 weeks prior to enrolment * Previous radiotherapy within 4 weeks prior to enrolment * Serious uncontrolled concurrent medical illness * History of severe hypersensitivity reaction…